The efficacy of modern pharmaceuticals often hinges on the precise chemical structure and purity of their constituent ingredients. In the realm of targeted cancer therapies, Vemurafenib, identified by its CAS number 1029872-54-5, plays a pivotal role. This article explores the chemistry of Vemurafenib, highlighting its importance as a pharmaceutical intermediate and the considerations for manufacturers and suppliers.

Vemurafenib, also known by its systematic name N-[3-[[5-(4-chlorophenyl)-1H-pyrrolo[2,3-b]pyridin-3-yl]carbonyl]-2,4-difluorophenyl]-1-propanesulfonamide, is characterized by its complex molecular structure. Its molecular formula is C23H18ClF2N3O3S, and it possesses a molecular weight of 489.92. This intricate structure is key to its specific mechanism of action as a BRAF V600E inhibitor, making it indispensable in the treatment of specific oncological conditions, most notably melanoma.

From a manufacturing perspective, the production of Vemurafenib requires sophisticated synthetic pathways to ensure high purity and yield. As a supplier of this critical intermediate, understanding the detailed chemical specifications is paramount. This includes not only the molecular formula and weight but also its physical appearance – typically an off-white solid – and its solubility characteristics. Vemurafenib is known to be soluble in solvents like DMSO and methanol, which are commonly used in pharmaceutical synthesis and formulation. Insoluble in ethanol and water, this solubility profile guides its handling and processing.

For chemical companies looking to buy Vemurafenib, understanding these chemical properties is crucial for integration into downstream processes. Whether a company is seeking a manufacturer for bulk supply or a supplier for research quantities, the consistent quality of the material is non-negotiable. The price of Vemurafenib will, of course, vary based on quantity and purity, but its value as a high-potency pharmaceutical intermediate remains undisputed.

The demand for compounds like Vemurafenib underscores the importance of specialized chemical manufacturers who can reliably produce complex organic molecules. As research in targeted therapies continues to advance, the need for high-quality pharmaceutical intermediates will only increase. Therefore, companies that can consistently deliver Vemurafenib, backed by robust quality assurance and competitive pricing, will be indispensable partners in the pharmaceutical industry's fight against cancer.